{"id":"chf5633","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CHF5633 is a CFTR corrector that aims to improve the function of the cystic fibrosis transmembrane conductance regulator protein, thereby alleviating the symptoms of cystic fibrosis.","oneSentence":"CHF5633 is a small molecule in development for the treatment of cystic fibrosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:26:27.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT02452476","phase":"PHASE2","title":"A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-01-21","conditions":"Respiratory Distress Syndrome, Newborn","enrollment":123},{"nctId":"NCT01651637","phase":"PHASE1","title":"First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-10","conditions":"Respiratory Distress Syndrome in Premature Infants","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CHF5633","genericName":"CHF5633","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHF5633 is a small molecule in development for the treatment of cystic fibrosis. Used for Treatment of cystic fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}